Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cullinan Metals Corp V.CMT


Primary Symbol: C.CMT Alternate Symbol(s):  CMTNF

Cullinan Metals Corp. is a Canadian mining and exploration company focused on the development of energy metals. The Company is focused on energy resources, such as copper, graphite and lithium assets. Its projects include Smiley Lithium Project, Lac-Des-Iles West Graphite Project and Wakeman Lake Lithium Project. The Smiley Lithium Property consists of around five mining claims comprising approximately 1,902 hectares located 55 kilometers (km) north of Thunder Bay, Ontario. The Smiley Lake Lithium property is located in northwestern Ontario where numerous lithium deposits have been delineated to host significant reserves of lithium oxide (Li2O). The Lac-Des-Iles West Graphite Project consists of around 43 mineral claims in one contiguous block covering approximately 2276 hectares land, near the town of Mont-Laurier in southern Quebec. The highly prospective Wakeman Lake Lithium Project covers approximately 7,900 acres and is located in Northwestern Ontario.


CSE:CMT - Post by User

Comment by Toweringmarson Feb 24, 2020 3:18pm
198 Views
Post# 30727456

RE:Read the Real Truth

RE:Read the Real Truth

Pitdigger wrote: Sebastian Diemer, Founder and Chairman of Farmako stated last year:

This is a big leap forward for millions of patients in Europe. The market for pharmaceutical cannabis is the fastest growing market worldwide. In Canada, the industry grew from 170 million to a 30 billion industry within three years. We aim to provide cost efficient and custom tailored cannabinoid therapies to support a similar success story for the European markets. When future historians write a history of entrepreneurship, the market liberalization of pharmaceutical cannabis will get a separate chapter. Dozens of investors are waiting in line to be a part of this story.”

Niklas Kouparanis, Founder and CEO of Farmako“This first step enables us to build a reliable distribution network in all European jurisdictions with a legal basis for pharmaceutical cannabis. The German is twice as big as the Canadian market, and additional European markets like the United Kingdom markets are opening up. We are in the unique position of reaping the full benefits of a second mover advantage: We adapt the smart moves of our predecessors and do not repeat their mistakes.”

Pharmacann Polska’s representative - Yuval Soiref, the Co-Founder, CEO and International Business Development: “This exclusive agreement is a great success and not only ensures stable supply of pharmaceutical cannabis, but also a beginning of research-based development of innovative cannabis strains for better and more targeted medical treatment. Thanks to our sophisticated growing systems and pharmaceutical-grade extraction, we are one of the very few players worldwide who are able to guarantee the highest quality cannabis in the largest amount ever seen in European history. Together with Farmako, we enter into an exclusive and promising partnership to move cannabinoid-based healthcare forward.” 

Farmako and Pharmacann Polska have agreed on a deep partnership in research and development. It focuses on the joint development of new custom-tailored cannabis strains, while using the full advantage of producing at a substantially lower cost in the eastern part of the EU. Kouparanis: “We will produce a higher quality medicine at a lower price than our Canadian competitors. The first pharmaceutical cannabis shipment is expected to be in German pharmacies by June 2019.” For the next four years, Pharmacann Polska will provide pharmaceutical Cannabis exclusively for Farmako. This finally ensures a stable supply for the German patients which Canadian suppliers could not guarantee in the past year. 

Germany will not be the only country to benefit from high-quality therapies with pharmaceutical cannabis. Kouparanis: "We will be active in every European jurisdiction that creates a legal basis. In the United Kingdom, Denmark and Luxembourg, pharmaceutical cannabis was also approved. Many more European countries will follow soon. We plan to become Europe's leading pharmaceutical cannabis company and to ensure security of supply in these countries as well. We guarantee that European cannabis for European patients is not only legal, but also affordable and available.”

To all you idiots that are attempting to trash AGRA, ask yourself who actually owns Farmako??

BTW - the above info was published into the Public Domain.

 

They lost me at  "In Canada, the industry grew from 170 million to a 30 billion industry within three years." Maybe thats how Farmako thinks it somehow has 8% market share... Gooder Maths. Meanwhile in Canada we're doing like 1.3b a year rec... Somehow medicinal must account for 28.7 billion dollars??? LOL 
 

<< Previous
Bullboard Posts
Next >>